Clinical trials: Pulmonary Disorder
Asthma
Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma
In both parts, the primary comparisons of interest are between the percentage of patients with drug-related adverse events at each dose and placebo during single and multiple dosing regimens.
- Trial name
- NCT03971539
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim
Asthma
Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.
The primary objective of this study is to assess the immunogenic potential of the liquid formulation of omalizumab administered over a period of 6 months in moderate to severe persistent allergic asthma patients 12 years of age…
- Trial name
- NCT00500539
- Testing
- omalizumab
- Where
- 31 sites in United States, Argentina and 1 more
- Volunteers
- 155 people
- Sponsor
- Novartis
Idiopathic Pulmonary Fibrosis
Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
The main objectives of this study are: Determine the difference in change from baseline in Six Minute Walk Distance (6MWD) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with…
- Trial name
- NCT03717012
- Testing
- Nintedanib, Pulmonary rehabilitation program
- Where
- 19 sites in United States
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
COVID-19
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19.
- Trial name
- NCT04411628
- Testing
- LY3819253
- Where
- 11 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Covid19
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in healthy participants
- Trial name
- NCT04532294
- Testing
- BGB DXP593
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BeiGene
Idiopathic Pulmonary Fibrosis
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic…
- Trial name
- BUILD OL (NCT00631475)
- Testing
- Bosentan
- Volunteers
- 128 people
- Sponsor
- Actelion
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III
Induction Chemo-Nivo in Unresectable Stage III NSCLC
The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer.
- Trial name
- NCT06003075
- Testing
- Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ralph G Zinner
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
The primary purpose of this study is to compare the number of participants with reversible pulmonary hypertension (vasoreactivity) due to nitric oxide for inhalation and oxygen as compared to 100% oxygen.
- Trial name
- NCT00626028
- Testing
- Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
- Where
- 18 sites in United States, France and 3 more
- Volunteers
- 136 people
- Sponsor
- Mallinckrodt
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pulmonary Arterial Hypertension
Remodulin® to Oral Treprostinil Transition
This multi-center, open-label study will assess the tolerability and safety of transitioning subjects with stable Pulmonary Arterial Hypertension (PAH) from continuous intravenous (IV) or subcutaneous (SC) Remodulin infusion to…
- Trial name
- NCT01588405
- Testing
- UT-15C SR
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- United Therapeutics
Non-Small Cell Lung Cancer
A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer
This was a Phase II, open-label, prospective, multicenter study designed to evaluate the efficacy and safety of single-agent atezolizumab as a first-line therapy in participants with locally advanced or metastatic non-small cell…
- Trial name
- B-F1RST (NCT02848651)
- Testing
- Atezolizumab
- Where
- 20 sites in United States
- Volunteers
- 153 people
- Sponsor
- Genentech, Inc.
Cystic Fibrosis
FDG-PET Imaging in Young Cystic Fibrosis Patients
The purpose of this research is to determine how a person's lungs will uptake [18F]fluorodeoxyglucose (FDG), as measured with positron emission tomography (PET) scanning in young cystic fibrosis (CF) patients.
- Trial name
- NCT00846053
- Testing
- FDG-PET
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Atopic Dermatitis, Eczema
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
There is a lack of prospective scientific data on the regular use of moisturizers in patients at risk of developing atopic dermatitis.
- Conditions
- Atopic Dermatitis, Eczema, Asthma, Food Allergies
- Trial name
- NCT01577628
- Testing
- Lipikar Balm AP
- Where
- 4 sites in United States, Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
COVID-19
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
- Trial name
- TACKLE (NCT04723394)
- Testing
- AZD7442
- Where
- 103 sites in United States, Argentina and 13 more
- Volunteers
- 910 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Cancer
Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)
This is a two-arm, parallel, open-label, Phase 2 multicenter study of pemetrexed as first line combination therapy with either cisplatin or carboplatin in the palliative setting of stage IIIb and IV non-small cell lung cancer…
- Trial name
- NCT00402051
- Testing
- Pemetrexed, Cisplatin, Carboplatin
- Where
- 12 sites in Germany
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
This phase II clinical trial is studying how well azacitidine works in treating patients with previously treated advanced non-small cell lung cancer.
- Trial name
- NCT01281124
- Testing
- Azacitidine, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Idiopathic Pulmonary Fibrosis (IPF)
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.
- Trial name
- NCT03832946
- Testing
- GB0139
- Where
- 128 sites in United States, Australia and 13 more
- Volunteers
- 172 people
- Sponsor
- Galecto Biotech AB
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del]…
- Trial name
- MARIPOSA (NCT04487080)
- Testing
- Amivantamab, Osimertinib, Lazertinib
- Where
- 269 sites in United States, Argentina and 26 more
- Volunteers
- 1,074 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Disease, Chronic Obstructive
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT01053988
- Testing
- FF/GW642444 Inhalation Powder, FF Inhalation Powder, GW642444 Inhalation Powder
- Where
- 132 sites in United States, Chile and 8 more
- Volunteers
- 1,031 people
- Sponsor
- GlaxoSmithKline
COVID-19
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from…
- Trial name
- APLICOV-PC (NCT04382066)
- Testing
- Plitidepsin 1.5 mg/day, Plitidepsin 2.0 mg/day, Plitidepsin 2.5 mg/day
- Where
- 13 sites in Spain
- Volunteers
- 46 people
- Sponsor
- PharmaMar
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.